← Leaderboards
Robert D Moir
Massachusetts General Hospital
$2,517,689
Attributed
$2,517,689
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $438.1K · FY2006–14$500K$375K$250K$125K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$2,517,689 · 2
By mechanism
R01$2,150,128 · 1
R21$367,561 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Frederick M Ausubel$22,351,893
- Galit Alter$32,273,423
- Roby Paul Bhattacharyya$4,624,355
- Kristopher Kahle$4,520,985
- Allison Carey$2,921,568
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsAnimal ModelMouse ModelPeptidesResearch StudyBrainImmunoreactivityMediatingNeurotoxicPathologyS DiseaseTg2576NeurotoxicityAlzheimer&AposAmyloid Beta-ProteinFutureAttenuatedIn VivoAntimicrobial PeptideAntimicrobial DrugAmyloidosisAntimicrobialBacterial ResistanceCells
Grant awards (7)
The Abeta protein of Alzheimer's Disease is an antimicrobial peptide$438,075
R01 · FY2014 · AI · contact PI
The Abeta protein of Alzheimer's Disease is an antimicrobial peptide$411,791
R01 · FY2013 · AI · contact PI
The Abeta protein of Alzheimer's Disease is an antimicrobial peptide$438,075
R01 · FY2012 · AI · contact PI
The Abeta protein of Alzheimer's Disease is an antimicrobial peptide$428,927
R01 · FY2011 · AI · contact PI
The Abeta protein of Alzheimer's Disease is an antimicrobial peptide$433,260
R01 · FY2010 · AI · contact PI
Targeting cross-linked amyloid protein species as a therapy for AD.$144,436
R21 · FY2007 · AG · contact PI
Targeting cross-linked amyloid protein species as a therapy for AD.$223,125
R21 · FY2006 · AG · contact PI